The company's research and development efforts are concentrated on a newly discovered area of biology called Physiocrine biology, which involves physiological modulators. aTyr Pharma has a pipeline of potential protein therapeutics, with their lead candidate, Resolaris, currently in clinical trials for the treatment of rare myopathies. The company has also built a strong intellectual property estate with numerous patents and pending patent applications. aTyr Pharma's key programs target severe, rare diseases characterized by immune dysregulation, where treatment options are limited. The company was founded by leading scientists in the field and is backed by top life sciences investors.